Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Troriluzole in Obsessive Compulsive Disorder
2024-514585-39-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Troriluzole adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Y-BOCS total score change from baseline. Started Jul 2024; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2024-514585-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514585-39-00.